WST
A quarter that didn’t show up empty-handed
West Pharmaceutical Services just served up a pretty tidy earnings package: adjusted EPS came in at $1.83 on $805 million in revenue, which was up 7.5% year over year. For a company that lives in the unglamorous but essential world of packaging and delivery systems for injectable drugs, that’s the kind of steady execution investors like to see.
The real headline: 2026 got a little friendlier
The company also set FY2026 EPS guidance of $7.85 to $8.20. That matters because guidance is where the market starts doing its little forward-looking dance — and in this case, West is signaling more profit power ahead, not just a one-quarter victory lap.
Cash? They’ve got ideas
Then came the shareholder treats:
- a new $1.0 billion repurchase program
- a $0.22 quarterly dividend
That’s management basically saying, “We think our stock is worth buying, and here’s some cash while we wait.” Not bad if you’re into companies that make boring look profitable.
The analyst peanut gallery is still chiming in
The backdrop here is that Wall Street has been tweaking its expectations too. Evercore cut its price target from $390 to $320 but kept an outperform rating, while Barclays nudged its target up to $275 and stayed at equal weight. Translation: the crowd is still debating how much upside is left, but no one’s exactly running for the exits.
Big picture: West Pharma’s quarter looks like a classic quality-stock setup — decent growth, upbeat guidance, and capital returns. If you’re holding it, the story is less “moonshot” and more “steady compounding with a dividend chaser.”